277 related articles for article (PubMed ID: 33408251)
1. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Xiao Y; Lin FT; Lin WC
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33408251
[TBL] [Abstract][Full Text] [Related]
2. Increased ACTL6A occupancy within mSWI/SNF chromatin remodelers drives human squamous cell carcinoma.
Chang CY; Shipony Z; Lin SG; Kuo A; Xiong X; Loh KM; Greenleaf WJ; Crabtree GR
Mol Cell; 2021 Dec; 81(24):4964-4978.e8. PubMed ID: 34687603
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
Kothandapani A; Gopalakrishnan K; Kahali B; Reisman D; Patrick SM
Exp Cell Res; 2012 Oct; 318(16):1973-86. PubMed ID: 22721696
[TBL] [Abstract][Full Text] [Related]
4. ACTL6A suppresses p21
Shrestha S; Adhikary G; Xu W; Kandasamy S; Eckert RL
Oncogene; 2020 Sep; 39(36):5855-5866. PubMed ID: 32616890
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
6. ACTL6A deficiency induces apoptosis through impairing DNA replication and inhibiting the ATR-Chk1 signaling in glioblastoma cells.
Hu X; Pei D; Ci M; Zhang G; Li B; Wang J; Shen Y; Zhai X; Liang P; Cui H
Biochem Biophys Res Commun; 2022 Apr; 599():148-155. PubMed ID: 35182941
[TBL] [Abstract][Full Text] [Related]
7. ACTL6a enforces the epidermal progenitor state by suppressing SWI/SNF-dependent induction of KLF4.
Bao X; Tang J; Lopez-Pajares V; Tao S; Qu K; Crabtree GR; Khavari PA
Cell Stem Cell; 2013 Feb; 12(2):193-203. PubMed ID: 23395444
[TBL] [Abstract][Full Text] [Related]
8. Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ.
Ji J; Xu R; Zhang X; Han M; Xu Y; Wei Y; Ding K; Wang S; Bin Huang ; Chen A; Di Zhang ; Jiang Z; Xu S; Zhang Q; Li W; Ni S; Wang J; Li X
Cell Death Dis; 2018 May; 9(5):517. PubMed ID: 29725063
[TBL] [Abstract][Full Text] [Related]
9. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
10. ACTL6A regulates follicle-stimulating hormone-driven glycolysis in ovarian cancer cells via PGK1.
Zhang J; Zhang J; Wei Y; Li Q; Wang Q
Cell Death Dis; 2019 Oct; 10(11):811. PubMed ID: 31649264
[TBL] [Abstract][Full Text] [Related]
11. ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
Saladi SV; Ross K; Karaayvaz M; Tata PR; Mou H; Rajagopal J; Ramaswamy S; Ellisen LW
Cancer Cell; 2017 Jan; 31(1):35-49. PubMed ID: 28041841
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK; Guo Y; Miller MR; Yu JJ
Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
[TBL] [Abstract][Full Text] [Related]
13. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition.
Xiao S; Chang RM; Yang MY; Lei X; Liu X; Gao WB; Xiao JL; Yang LY
Hepatology; 2016 Apr; 63(4):1256-71. PubMed ID: 26698646
[TBL] [Abstract][Full Text] [Related]
14. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
15. Actin-like 6A enhances the proliferative and invasive capacities of laryngeal squamous cell carcinoma by potentiating the activation of YAP signaling.
Dang Y; Zhang L; Wang X
J Bioenerg Biomembr; 2020 Dec; 52(6):453-463. PubMed ID: 33067739
[TBL] [Abstract][Full Text] [Related]
16. Actin-like Protein 6A Expression Correlates with Cancer Stem Cell-like Features and Poor Prognosis in Ovarian Cancer.
Chen PM; Wong CN; Wong CN; Chu PY
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768349
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex.
Panatta E; Lena AM; Mancini M; Smirnov A; Marini A; Delli Ponti R; Botta-Orfila T; Tartaglia GG; Mauriello A; Zhang X; Calin GA; Melino G; Candi E
EMBO Rep; 2020 Mar; 21(3):e46734. PubMed ID: 32017402
[TBL] [Abstract][Full Text] [Related]
18. ACTL6A expression promotes invasion, metastasis and epithelial mesenchymal transition of colon cancer.
Zeng Z; Yang H; Xiao S
BMC Cancer; 2018 Oct; 18(1):1020. PubMed ID: 30348114
[TBL] [Abstract][Full Text] [Related]
19. The role of DNA repair pathways in cisplatin resistant lung cancer.
O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP
Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603
[TBL] [Abstract][Full Text] [Related]
20. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
